SCHEMBL7657337

SCHEMBL7657337

COc1ccccc1-n1[nH]c(-c2ccccc2)nc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.46
TNKS O95271 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
RECQL P46063 1/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.43
APOBEC3G Q9HC16 1/20 0.43
ADORA3 P0DMS8 2/20 0.43
ADORA1 P30542 2/20 0.43
AVPR2 P30518 1/20 0.42
AVPR1A P37288 1/20 0.42
HTT P42858 2/20 0.41
ADORA2A P29274 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7652870 0.81 KDM4E (0.44) MGLLTNKSTNKS2ALDH1A1KDM4E
SCHEMBL7654106 0.79 MGLL (0.44) MGLLALDH1A1KDM4EADORA3ADORA1
SCHEMBL7654354 0.78 MEN1 (0.44) MGLLALDH1A1KDM4EMEN1KMT2A
SCHEMBL7652337 0.78 KDM4E (0.44) MGLLTNKSTNKS2ALDH1A1KDM4E
SCHEMBL7650494 0.78 KDM4E (0.45) MGLLALDH1A1KDM4EMEN1KMT2A
SCHEMBL7653827 0.77 KDM4E (0.48) TNKSTNKS2RECQLALDH1A1KDM4E
SCHEMBL7656036 0.75 ALKBH5 (0.50) MGLLALDH1A1KDM4EHTTMEN1
SCHEMBL7650665 0.75 KDM4E (0.64) ALDH1A1KDM4EAPOBEC3GMEN1KMT2A
SCHEMBL7652917 0.74 GAA (0.52) ALDH1A1KDM4EAPOBEC3GMEN1KMT2A
SCHEMBL7659636 0.74 MEN1 (0.51) TNKSTNKS2ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6492407-B2 NEUROPROTECTIVE ACTIVITY BOEHRINGER IMGELHEIM PHARMA KG (DE) 2002-12-10 US claimed
US-20020045651-A1 Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-04-18 US claimed
US-6492407-B2 NEUROPROTECTIVE ACTIVITY BOEHRINGER IMGELHEIM PHARMA KG (DE) 2002-12-10 US disclosed
US-20020045651-A1 Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045651-A1 Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones PARK7, IAPP, HIF1AN MGLL 4482/4885TNKS 607/4885TNKS2 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.